Growth that matters
Private equity focused on Biosciences in the Iberian Lower Mid-Market
The Firm
Aleos Capital is an institutional private equity platform founded in 2025. We partner with high-potential biosciences companies in the Iberian lower mid-market, supporting their next stage of growth. We combine investment discipline, hands-on ownership and sector expertise to build more scalable, resilient and sustainable businesses
Target Market
We specialize in Biosciences within the Iberian Lower Mid-Market
Biosciences
Investing in human & environmental health
3 verticals with growing sub-segments
Iberia
A fragmented market, with significant potential to increase scale
Spain and Portugal
Lower Mid - Market
An underserved market, full of opportunities
Growing €2m–€8m EBITDA Small and Medium Enterprises
Biosciences specialization
We invest in companies that improve human and environmental health, across three verticals
Health & Wellness
Improved healthcare and quality of life for individuals and communities
SELECTED SUBSEGMENTS
CONSUMER HEALTH
HEALTHCARE DIAGNOSTICS
MED TECH
HEALTHCARE IT
PHARMA SERVICES
ANIMAL HEALTH
Sustainable Nutrition
Healthy & safe nutrition, produced in a mindful way for the planet and society
SELECTED SUBSEGMENTS
NUTRACEUTICALS
ALTERNATIVE PROTEINS
FOOD DIAGNOSTICS
SUSTAINABLE PACKAGING
NUTRITIOUS FOOD
FOOD TECH
Climate & Environment
Preservation of the planet through sustainable practices & innovative solutions
SELECTED SUBSEGMENTS
CLIMATE MONITORING
CIRCULAR ECONOMY
AGRI BIOSOLUTIONS
WASTE MANAGEMENT
ENERGY TRANSITION
CLEANTECH
Why Biosciences
An attractive investment theme at the intersection of growth, innovation and impact
Global Megatrends
STRUCTURAL GROWTH
Supported by powerful long-term trends that continue to drive innovation, investment and demand across the Biosciences ecosystem
Iberian Leadership
DISTINCTIVE KNOW-HOW
Leading capabilities across healthcare, nutrition and environmental solutions
Aleos Expertise
SECTOR SPECIALIZATION
Deep investment and operational expertise in Biosciences
Investment Approach
We accelerate sustainable growth by supporting high-quality companies through active ownership, management alignment and tailored capital structures
Value Creation Strategy
We drive growth and returns through a 5-lever operational program, reinforced by Aleos Biosciences expertise
Industry consolidation
Creating category leaders through buy-and-build strategies
Internationalization
Accelerating targeted global expansion, leveraging existing strengths
Technology & AI
Deploying technology to scale faster and enhance efficiency
Management Reinforcement
Strengthening teams, alignment and governance
Sustainability
Implementing sustainability programs to drive long-term value
Investor Base
In its first closing in February 2026, Aleos Fund I secured over €150 million, surpassing its target size.
A larger final close is expected in the coming months
Diversified LP base
The current LP base is diversified, including local and international institutional investors, family offices and individuals, with strong alignment of interests and a meaningful GP commitment
No single investor represents more than 25% of total commitments
LPs by investor type
■ Institutions · 51%
■ Family Offices · 25%
■ Individuals + GP Commitment · 24%
The Team
A team combining deep private equity and operational expertise across the Biosciences ecosystem.
Founded in 2025 by Héctor Ciria and David Santos, Aleos Capital was established with the ambition of building a leading private equity platform in the Biosciences space. The firm brings together a cohesive team with complementary investment, operational and sector expertise, united by a hands-on approach to value creation and a long-term partnership mindset
Portfolio
Our first investment reflects the type of company we seek to support: a high-growth, innovative business with a top-tier team, international reach, and a leading position in a Biosciences sector driven by favourable macro trends
EGGNOVO
Biosciences Verticals
Climate & Environment - Sustainable Nutrition - Health & Wellness
Investment Year 2026
Website www.eggnovo.com
European leader in branded natural functional ingredients derived from eggshell membrane, with a strong international footprint. Using a circular economy model and proprietary technology, the company sustainably produces a matrix of over 400 high-purity bioactive compounds for nutraceutical applications in joint and skin health
Sustainability
We aim to generate long-term value across our broader ecosystem through active and responsible ownership, sustainable growth, and ESG-led investment practices
Management Company Commitment
Responsible investment aligned with leading international sustainability frameworks
Sustainability Across the Investment Cycle
Sustainability criteria integrated across sourcing, due diligence, investment decision-making, ownership and exit, ensuring ESG considerations are embedded throughout the full investment cycle
Active Portfolio Engagement
Close work with portfolio companies to implement clear sustainability priorities, strengthen governance and monitor progress throughout the holding period